Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.

Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill ME, Hoersch S, Rittweger K, Haller DG.
J Clin Oncol. 2015 33:3733-40

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.

Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill ME, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P
Lancet Oncol. 2013 14:749-59

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).

Middleton G, Brown S, Lowe C, Maughan T, Gwyther S, Oliver A, Richman S, Blake D, Napp V, Marshall H, Wadsley J, Maisey N, Chau I, Hill ME, Gollins S, Myint S, Slater S, Wagstaff J, Bridgewater J, Seymour M
Eur J Cancer. 2013 49 :3507-16

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer

Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill ME, Gilberg F, Rittweger K, Schmoll HJ
J Clin Oncol. 2011 29:1465-71

Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients

Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill ME, Sirzen F, Haller DG
J Clin Oncol. 2007 25:102-109

Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer

Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill ME, Ross PJ, Massey A, Oates JR
J Clin Oncol. 2006 24:668-674

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.

Chau I, Norman A, Cunningham D, Tait D, Ross J, Iveson T, Hill ME, Hickish T, Lofts F, Jodrell D, Webb A, Oates JR
Ann Oncol. 2005 16:549-57

The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.

Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HF, Tebbutt N, Tait D, Hill ME, Ross PJ, Oates JR
J Clin Oncol. 2004 22:1420-9

Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling.

Clarke PA, George ML, Easdale S, Cunningham D, Swift RI, Hill ME, Tait DM, Workman P
Cancer Res. 2003 63:6855-63

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.

Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O'Brien M, Tebbutt N, Harrington A, Hill M.
J Clin Oncol. 2002 20: 3130-6